## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, or claims in the application.

**Listing of Claims**:

1 - 9 (Canceled).

10(Previously Presented). The vector according to claim 19, wherein said vector is selected from the group consisting of an adeno-associated viral vector and a plasmid vector.

11.Canceled.

12(Previously Presented). The pharmaceutical composition according to claim 20, wherein the carrier is a buffered saline solution.

Claims 13-18. Canceled.

19 (Currently Amended). A vector comprising a nucleic acid sequence encoding microutrophin under the control of regulatory sequences which direct expression of the microutrophin in a host cell, wherein the microutrophin comprises an N-terminal region of utrophin comprising hinge region 1, at least four utrophin central rod repeats, an internal deletion from repeat 4 through repeat 21, hinge region 4, and a deletion in the C-terminal utrophin region relative to human utrophin.

20 (Previously Presented). A pharmaceutical composition comprising a vector according to claim 19 and a physiologically compatible carrier.

Claim 21. Cancelled.

22 (Previously Presented). The vector according to claim 19, wherein the microutrophin comprises a C-terminal deletion from exon 63 through the C-terminal amino acid of the native utrophin protein.

23 (Previously Presented). The vector according to claim 19, wherein the microutrophin comprises the N-terminal sequences of utrophin through at least two hinge regions, and a C-terminal region from repeat 22 through exon 63.

Claim 24. Cancelled.

25 (Previously Presented). The vector according to claim 19, wherein the regulatory sequences comprise a constitutive promoter.

26 (Previously Presented). The vector according to claim 19, wherein the regulatory sequences comprise a muscle-specific promoter.

27 (New). A vector comprising a nucleic acid sequence encoding microutrophin under the control of regulatory sequences which direct expression of the microutrophin in a host cell wherein the microutrophin is human microutrophin having the amino acid sequence of SEQ ID NO: 4.

28 (New). The vector according to claim 27, wherein said vector is an adeno-associated viral vector.

29 (New). A pharmaceutical composition comprising a vector according to claim 28 and a physiologically compatible carrier.

30(New). The pharmaceutical composition according to claim 29, wherein the carrier is a buffered saline solution.

31 (New). A vector comprising a nucleic acid sequence encoding microutrophin under the control of regulatory sequences which direct expression of the microutrophin in a host cell wherein the microutrophin is canine microutrophin having the amino acid sequence of SEQ ID NO:2.

32 (New). A vector comprising a nucleic acid sequence encoding microutrophin under the control of regulatory sequences which direct expression of the microutrophin in a host cell wherein the microutrophin is microutrophin having the amino acid sequence of SEQ ID NO:5.